FDI In Biotechnology Sectors

The biotechnology sector in the country has played a significant role in enhancing India’s global profile. India stands among the top 12 biotech destinations in the world and ranks third in the Asia Pacific. FDI for the biotechnology sectors encouraged in India. The country has the second-highest number of US Food and Drug Administration (USFDA)–approved plants, after the USA and is the largest producer of recombinant Hepatitis B vaccine. FDI in biotechnology in India is expected to grow in the coming years.

Indian biotechnology industry is estimated to reach USD 11.6 billion by FY17 while growing at a CAGR of 20.3% during FY05-17. It witnessed the y.o.y. the growth of 57.1% in FY16 compared to FY15.


Industry Scenario

India's Serum Institute is the largest Bio-Pharma company in the country and accounts for approximately 22% of the biopharma market.

30 bio-incubators and biotech parks have been supported and established from April 2014-September 2016.


  • 1
    World's largest producer of recombinant Hepatitis B vaccine
  • 2
    World's largest producer of BT Cotton
  • 3
    World's second highest number of USFDA approved plants



1. July 2016 Helix investment Holdings Pte Ltd., Singapore invested USD 12 mn in Concord Biotech Ltd

2. August 2015 - Tano India Pvt., Mauritius invested USD 7.4 mn in Windlas Biotech Ltd.

FDI Facts

100 % FDI allowed in greenfield projects

74% FDI allowed in brownfield projects

100% FDI allowed in the manufacturing of medical devices